<DOC>
	<DOCNO>NCT00034502</DOCNO>
	<brief_summary>This non-randomized study patient receive prior 5-FU therapy colorectal cancer . The objective trial establish maximum tolerate dose ALIMTA irinotecan give combination well assess safety efficacy combination patient locally advance metastatic colorectal cancer . ALIMTA irinotecan give every 21 day .</brief_summary>
	<brief_title>A Trial ALIMTA ( Pemetrexed ) Plus Irinotecan Patients Who Have Been Previously Treated For Metastatic Colorectal Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histologic cytologic diagnosis locally metastatic colorectal cancer Prior therapy 5FU metastatic cancer Adequate bone marrow , liver kidney function Pregnancy Breast feed Inability interrupt aspirin therapy Brain metastasis Patients treat previously ALIMTA irinotecan</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2006</verification_date>
</DOC>